icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
NtGw4HLVntb3ZkXZ